Search

Your search keyword '"Tybjaerg-Hansen, Anne"' showing total 55 results

Search Constraints

Start Over You searched for: Author "Tybjaerg-Hansen, Anne" Remove constraint Author: "Tybjaerg-Hansen, Anne" Database OpenAIRE Remove constraint Database: OpenAIRE
55 results on '"Tybjaerg-Hansen, Anne"'

Search Results

1. Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines

2. Author Correction: Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

3. Publisher Correction : Stroke genetics informs drug discovery and risk prediction across ancestries

4. ANGPTL7, a therapeutic target for increased intraocular pressure and glaucoma

5. rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis

6. Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies

7. rs641738C>T near MBOAT7 promotes steatosis, NASH, fibrosis and hepatocellular carcinoma in non-alcoholic fatty liver disease: a meta-analysis

8. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm : conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

9. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential

10. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential: a consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

11. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation

12. Steroid receptor coactivator-1 modulates the function of Pomc neurons and energy homeostasis

13. Cardiovascular risk factors are associated with venous thromboembolism

14. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential

15. Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies

16. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

17. Rare and low-frequency coding variants alter human adult height

18. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies

19. Relationship between genetic variation at PPP1R3B and levels of liver glycogen and triglyceride

20. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes

21. Additional file 5: of Genetic variation in clusterin and risk of dementia and ischemic vascular disease in the general population: cohort studies and meta-analyses of 362,338 individuals

22. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

23. Additional file 2: of Genetic variation in clusterin and risk of dementia and ischemic vascular disease in the general population: cohort studies and meta-analyses of 362,338 individuals

24. Additional file 1: of Genetic variation in clusterin and risk of dementia and ischemic vascular disease in the general population: cohort studies and meta-analyses of 362,338 individuals

25. Additional file 5: of Genetic variation in clusterin and risk of dementia and ischemic vascular disease in the general population: cohort studies and meta-analyses of 362,338 individuals

26. Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease

27. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

28. The UK10K project identifies rare variants in health and disease

29. Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms

30. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

31. Association ofLPAVariants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies

32. Familial hypercholesterolaemia in children and adolescents : gaining decades of life by optimizing detection and treatment

33. Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis

34. Assessing Risk Prediction Models Using Individual Participant Data From Multiple Studies

35. Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study

36. AT1 mutations and risk of atrial fibrillation based on genotypes from 71 000 individuals from the general population

37. PCSK9R46L, Low-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease 3 Independent Studies and Meta-Analyses

38. Nonfasting Glucose, Ischemic Heart Disease, and Myocardial Infarction A Mendelian Randomization Study

39. Does Elevated C-Reactive Protein Increase Atrial Fibrillation Risk? A Mendelian Randomization of 47,000 Individuals From the General Population

40. Apolipoprotein E genotype: epsilon32 women are protected while epsilon43 and epsilon44 men are susceptible to ischemic heart disease The Copenhagen City Heart Study

41. Platelet glycoprotein IIb/IIIa PlA2/PlA2homozygosity associated with risk of ischemic cardiovascular disease and myocardial infarction in young men The Copenhagen City Heart Study

42. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores

43. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

44. Additional file 4: of Genetic variation in clusterin and risk of dementia and ischemic vascular disease in the general population: cohort studies and meta-analyses of 362,338 individuals

45. New insights on the genetic etiology of Alzheimer’s and related dementia

46. Additional file 4: of Genetic variation in clusterin and risk of dementia and ischemic vascular disease in the general population: cohort studies and meta-analyses of 362,338 individuals

47. Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms

48. Additional file 3: of Genetic variation in clusterin and risk of dementia and ischemic vascular disease in the general population: cohort studies and meta-analyses of 362,338 individuals

49. Additional file 3: of Genetic variation in clusterin and risk of dementia and ischemic vascular disease in the general population: cohort studies and meta-analyses of 362,338 individuals

50. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity

Catalog

Books, media, physical & digital resources